BMP Sunstone Corporation signed a non-binding letter of intent to acquire 75% of Zhangjiakou Shengda Pharmaceutical Co., Ltd, a subsidiary of the Zhangjiakou Pharmaceutical Group, at a price of up to 30.0 million RMB ($4.4 million). For BMP Sunstone, the logic behind the acquisition is provided by the pediatric pharmaceutical focus of Shengda. Shengda concentrates on antibiotic R&D and boasts 75 SFDA product licenses. BMP Sunstone said Shengda’s products will extend BMP’s GoodBaby line of OTC and prescription products. More details...

Stock Symbol: (NSDQ: BJGP)